Abbvie IncChange company Symbol lookupSelect an option...ABBV Abbvie IncRPRX Royalty Pharma PLCNUE Nucor CorpMORN Morningstar IncTOP TOP Financial Group LtdVEEV Veeva Systems IncETY Eaton Vance Tax-Managed Diversified Equity Income FundFDX FedEx CorpTARO Taro Pharmaceutical Industries LtdTIO Tingo Group IncGo
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
RPRX Royalty Pharma PLC
NUE Nucor Corp
MORN Morningstar Inc
TOP TOP Financial Group Ltd
VEEV Veeva Systems Inc
ETY Eaton Vance Tax-Managed Diversified Equity Income Fund
FDX FedEx Corp
TARO Taro Pharmaceutical Industries Ltd
TIO Tingo Group Inc
Health Care : Biotechnology | Large Cap Value
Company profileAbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
| Latest Earnings Met Consensus (Q1 ending 03/2023) | Next Earnings Announcement | ||||
|---|---|---|---|---|---|
| Q1 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced April 27, 2023 | $2.46 | Q1 Estimate range of 14 analysts | $2.36 to $2.64 | Q2 Earnings will announce | (Unconfirmed) July 27, 2023 |
Quarterly Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
ABBV's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.